利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.023 秒)

    Use of conantokins
    6.
    发明授权
    Use of conantokins 失效
    使用柯南金

    公开(公告)号：US06399574B1

    公开(公告)日：2002-06-04

    申请号：US09533889

    申请日：2000-03-22

    申请人： R. Tyler McCabe ,  Li-Ming Zhou ,  Richard T. Layer ,  Baldomero M. Olivera ,  J. Michael McIntosh

    发明人： R. Tyler McCabe ,  Li-Ming Zhou ,  Richard T. Layer ,  Baldomero M. Olivera ,  J. Michael McIntosh

    IPC分类号： A61K3800

    CPC分类号： C07K14/43504 ,  A61K38/00

    摘要： The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include, epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-complusive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.

    摘要翻译： 本发明涉及使用具有10-30个氨基酸，包括优选两个或更多个γ-羧基谷氨酸残基的共同称为聚对二聚腺嘌呤肽，柯南多肽衍生物和柯南多肽嵌合体用于治疗神经病学和 精神障碍，如抗惊厥剂，神经保护剂或止痛剂。 神经系统疾病和精神障碍包括癫痫，惊厥，神经毒性损伤（与缺氧，缺氧或局部缺血，脑卒中，脑或脊髓创伤，心肌梗塞，身体创伤，溺水，窒息，围产期窒息， 或低血糖事件），神经变性（与阿尔茨海默病，老年性痴呆，肌萎缩性侧索硬化症，多发性硬化症，帕金森氏病，亨廷顿病，唐氏综合征，柯萨科夫病，精神分裂症，艾滋病痴呆，多发性梗塞性痴呆，Binswanger痴呆和神经元损伤有关 不安全的癫痫发作），化学毒性（如成瘾，吗啡耐受，阿片剂耐受性，阿片样物质耐受性和巴比妥耐受性），疼痛（急性，慢性，偏头痛），焦虑，重性抑郁症，躁狂抑郁症，强迫症 - 精神分裂症 和情绪障碍（如双相情感障碍，单极痴呆） 肌力障碍和季节性有效障碍）和肌张力障碍（运动障碍），睡眠障碍，肌肉松弛和尿失禁。 此外，凝血因子可用于治疗艾滋病毒感染，眼科指征和记忆，学习或认知缺陷。

    Process for producing an H2-CO gas mixture
    8.
    发明授权
    Process for producing an H2-CO gas mixture 失效
    生产H2-CO气体混合物的方法

    公开(公告)号：US06284157B1

    公开(公告)日：2001-09-04

    申请号：US09220604

    申请日：1998-12-28

    申请人： Baldur Eliasson ,  Ulrich Kogelschatz ,  Li-Ming Zhou

    发明人： Baldur Eliasson ,  Ulrich Kogelschatz ,  Li-Ming Zhou

    IPC分类号： C07C102

    CPC分类号： C01B3/342 ,  Y02P20/142

    摘要： In a discharge reactor with a low-current gas discharge, an inlet gas made of a CH4—CO2 gas mixture is converted into a synthesis gas having an H2—CO gas mixture which has a higher energy content than the inlet gas. For a predeterminable synthesis gas volume ratio R=H2/CO, the requisite CO2 proportion in the inlet gas can be derived from a function curve (f) or calculated according to V=−4.76·R3+37.57·R2−99.13·R+105.39.

    摘要翻译： 在具有低电流气体放电的放电反应器中，将由CH 4 -CO 2气体混合物制成的入口气体转化为具有比入口气体更高的能量含量的H 2 -CO气体混合物的合成气。 对于可预测的合成气体积比R = H2 / CO，入口气体中所需的CO 2比例可以从函数曲线（f）导出，或根据